Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00055926 · ClinicalTrials.gov registry record · Phase 1
CP-724,714 in Treating Patients With Metastatic Breast Cancer
A Phase 1 study of Breast Cancer, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT00055926: Completed Phase 1 study of Breast Cancer, sponsored by Jonsson Comprehensive Cancer Center.
NCT00055926 is a Phase 1 study of Breast Cancer that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 9 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00055926, a Phase 1 study of Breast Cancer, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: CP-724,714 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase I trial to study the effectiveness of CP-724,714 in treating patients who have metastatic HER2-overexpressing breast cancer.
Conditions Studied
Interventions
- DRUG CP-724,714
Study Locations (1)
California
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2003-01 |
| Est. Completion | 2005-05 |
| Phase | Phase 1 |
What the finished NCT00055926 record still lists
NCT00055926 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which CP-724,714 is the first listed.
NCT00055926 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00055926 about?
NCT00055926 is a clinical study titled "CP-724,714 in Treating Patients With Metastatic Breast Cancer". RATIONALE: CP-724,714 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase I trial to study the effectiveness of CP-724,714 in treating patients who have metastatic HER2-overexpressing breast cancer.
What is the current status of trial NCT00055926?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2003-01. Estimated completion is 2005-05.
What conditions does trial NCT00055926 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00055926?
The interventions under investigation include: CP-724,714 (DRUG).
Who is sponsoring clinical trial NCT00055926?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00055926 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00055926's enrollment target sits among peer trials
9 1190th of 1224 higher than 30 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia